Novo diabetes site adds new tools to self-manage

Share this article:
Novo Nordisk has unveiled a revamped diabetes care Web site to communicate with patients seeking help in the self-management of the disease.

ChangingDiabetes-us.com features new tools and content developed in response to findings from the Diabetes Attitudes, Wishes and Needs (DAWN) study, a 5,426-patient survey commissioned by Novo Nordisk.

“The DAWN Study has given us valuable insights into how people cope with diabetes at diagnosis and throughout the disease process,” said Susan Harrow Rago, associate director, patient services & professional relations, in a statement.

According to Rago, the site’s new tools will help diabetes patients collaborate more effectively to develop treatment programs tailored to their individual needs.

Content highlights include:
• Guide Me—a feature allowing diabetes patients to customize the site content based on their personal diagnosis.
• Diabetes Care Plan—an interactive tool that helps users track, manage and set goals for their diabetes care.
• My Priorities—a feature to help patients develop personal diabetes care goals and a psychosocial profile.

Users can also sign up to receive regular e-mail communications on diabetes topics from Novo Nordisk and link to divabetic.org, a diabetes outreach site for women.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.